Highlights:

• AU$407 million of new contracts sets up another potentially powerful growth cycle.
• Six-from-six renewals reinforce customer retention despite an increasingly competitive technology landscape.
• Digital pathology and AI reporting could unlock fresh revenue beyond core radiology.

Strong FY26 Earnings GrowthPro Medicus Limited (ASX: PME) announced its FY26 full-year results on 18 August 2026, delivering another strong year as demand for its enterprise medical imaging technology expanded. Revenue climbed 22.9% to AU$261.7 million, while underlying NPAT advanced 24.1% to AU$144.7 million. Reported NPAT surged 130.3% to AU$265.3 million, although this included substantial fair-value gains on financial assets.Underlying Growth Remains StrongThe underlying numbers show that operational momentum remained robust despite currency headwinds. On a constant-currency basis, revenue increased 28.4% to AU$273.5 million, underlying EBIT rose 30.6% to AU$206.0 million, and underlying NPAT expanded 32.5% to AU$154.5 million.

Profitability also strengthened, with the underlying EBIT margin reaching 74.9%, up 90 basis points. Meanwhile, Pro Medicus ended FY26 debt-free with AU$252.3 million in cash and other financial assets, providing considerable flexibility for product development, strategic investments and shareholder returns.Contract Wins Build Revenue VisibilityCommercial activity was another standout. Pro Medicus secured 10 new contracts worth AU$407 million, including a 10-year, AU$170 million agreement with UCHealth Colorado and a seven-year, AU$90 million deal with Beth Israel Lahey Health. Six existing contracts worth AU$141 million were also renewed on five-year terms.

Forward contracted recurring revenue over the next five years reached approximately AU$1.34 billion, up 41.3% over 12 months, strengthening visibility over future income.FY27 Outlook: Implementations Could Drive the Next StepFY27 could benefit from contracts already moving into production. Pro Medicus completed 16 implementations during FY26, including four Trinity Health cohorts, with management expecting the full-year contribution from these deployments to lift transaction revenue.

Beyond implementation-led growth, cardiology, digital pathology and AI-optimised reporting broaden the company’s addressable market. With a strong pipeline, high recurring contract visibility and a debt-free balance sheet, the key question for FY27 is whether Pro Medicus can translate its expanding customer footprint into another year of high-margin earnings growth.Note- All data presented is based on information available at the time of writing.Disclaimer for Kapitales ResearchThe materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au